<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65376">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01815138</url>
  </required_header>
  <id_info>
    <org_study_id>13-098-3</org_study_id>
    <nct_id>NCT01815138</nct_id>
  </id_info>
  <brief_title>Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS</brief_title>
  <official_title>A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut Health Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a prospective randomized double blind study involving patients at high risk of OHSS
      development with peak serum E2 levels &lt; 4,000 pg/ml comparing the ongoing pregnancy rates in
      patients who receive adjuvant hCG 1,000 IU at the time of GnRH agonist trigger or adjuvant
      hCG 1,500 IU 35 hours after GnRH agonist trigger.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian
      hyperstimulation which may result in significant morbidity and rarely mortality as well as
      significant financial and psychological distress. GnRH agonist trigger has been shown to be
      effective in OHSS prevention. However, the adoption of its use has not been widely accepted
      in view of concerns regarding potential impairment of implantation.

      Intensive luteal phase supplementation with estrogen (E2) and progesterone (P) is important
      due to the strong evidence of abnormal luteal phase serum E2 and P profiles. However, it has
      been shown that optimal conception rates is not achieved for high risk patients with peak
      serum E2 &lt; 4,000 pg/ml despite aggressive steroidal supplementation. It has been proposed
      that the use of adjuvant low dose hCG at the time of GnRH agonist trigger or 35 hours later
      will rescue some of the corpora lutea and help improve corpora lutea function and improve
      pregnancy rates.

      The study will evaluate patients at high risk of OHSS development with peak serum E2 &lt; 4,000
      pg/mL to determine whether timing of low dose hCG administration affects ongoing pregnancy
      rates or risk of OHSS. Markers of corpus luteum function such as serum 17
      hydroxy-progesterone and prorenin during the luteal phase and early pregnancy will help
      elucidate further the effect of adjuvant low dose hCG with GnRH agonist trigger on corpus
      luteum function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>Pregnancy beyond 7 weeks gestation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive serum pregnancy test and ultrasound evidence of fetal pole and fetal heart rate beyond 12 weeks gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian hyperstimulation syndrome</measure>
    <time_frame>Within 4 weeks of oocyte retrieval</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of symptoms and signs of OHSS at 9 days after trigger of oocyte maturation. Patients who also present with symptoms of OHSS wil also be evaluated for OHSS within 4 weeks after oocyte maturation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Markers of Corpus Luteum function</measure>
    <time_frame>Within 60 days after trigger of oocyte maturation</time_frame>
    <safety_issue>No</safety_issue>
    <description>A subset of patients (20 patients in each group) will have serum frozen for subsequent analysis of 17 hydroxy progesterone and prorenin.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Within 2 weeks after trigger of oocyte maturation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will complete a questionnaire to determine if there is a difference in the effect of the intervention on the quality of life of the patients from the day of trigger of oocyte maturation until menses or positive pregnancy test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>hCG given at time of GnRHa trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
Placebo administered 35 hours after GnRH agonist trigger</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG given 35 hours after GnRHa trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo administered at the time of GnRH agonist trigger
Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger</description>
    <arm_group_label>hCG given at time of GnRHa trigger</arm_group_label>
    <other_name>Pregnyl, Profasi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger</description>
    <arm_group_label>hCG given 35 hours after GnRHa trigger</arm_group_label>
    <other_name>Pregnyl, Profasi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal baseline serum follicle stimulating hormone, polycystic ovarian syndrome
             (PCOS), Polycystic ovarian morphology, Previous high responder or previous OHSS, must
             have &gt; 14 follicles of over 11 mm in diameter and with peak serum E2 levels &lt; 4,000
             pg/mL on the day of trigger of oocyte maturation.

        Exclusion Criteria:

          -  Hypothalamic dysfunction, Patients with &lt; 14 follicles &lt; 11 mm in diameter, peak
             serum E2 levels &gt;= 4,000 pg/mL.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Engmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Piscatelli, BS, CCRP</last_name>
    <phone>869 679 4612</phone>
    <email>piscatelli@adp.uchc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Piscatelli, BS, CCRP</last_name>
      <phone>860-679-4612</phone>
      <email>piscatelli@adp.uchc.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Engmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril. 2012 Jun;97(6):1316-20. doi: 10.1016/j.fertnstert.2012.03.015. Epub 2012 Apr 3.</citation>
    <PMID>22480822</PMID>
  </reference>
  <reference>
    <citation>Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril. 2011 Jul;96(1):63-8. doi: 10.1016/j.fertnstert.2011.04.050. Epub 2011 May 12.</citation>
    <PMID>21565337</PMID>
  </reference>
  <reference>
    <citation>Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008 Jan;89(1):84-91. Epub 2007 Apr 26.</citation>
    <PMID>17462639</PMID>
  </reference>
  <reference>
    <citation>Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online. 2009 May;18(5):630-4.</citation>
    <PMID>19549440</PMID>
  </reference>
  <reference>
    <citation>Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006 Aug;13(2):173-8.</citation>
    <PMID>16895629</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 18, 2013</lastchanged_date>
  <firstreceived_date>March 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut Health Center</investigator_affiliation>
    <investigator_full_name>Lawrence Engmann</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>OHSS, GnRH agonist trigger, low dose hCG, PCOS, IVF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
